Dow Up0.65% Nasdaq Up0.83%

Illumina Inc. (ILMN)

135.36 Up 0.37(0.27%) 3:30PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Illumina Inc.
5200 Illumina Way
San Diego, CA 92122
United States - Map
Phone: 858-202-4500

Index Membership:N/A
Full Time Employees:N/A

Business Summary 

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company’s sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Illumina Inc.

Corporate Governance 
Illumina Inc.’s ISS Governance QuickScore as of May 1, 2016 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 9; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Jay T. Flatley , 63
Chairman and Chief Exec. Officer
Mr. Francis A. deSouza , 45
Pres and Director
Dr. David R. Walt Ph.D., 63
Founder, Director and Member of Nominating & Corp. Governance Committee
Mr. Marc A. Stapley , 46
Chief Financial Officer, Chief Admin. Officer and Exec. VP
Mr. Tristan B. Orpin , 50
Exec. VP of Clinical Genomics
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders